Westermann AM - Search Results

1

Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.

Westermann AM, Taal BG, Swart M, Boot H, Craanen M, Gerritsen WR. Westermann AM, et al. Pharmacol Res. 2000 Aug;42(2):151-6. doi: 10.1006/phrs.2000.0677. Pharmacol Res. 2000. PMID: 10887044 Clinical Trial.

2

Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.

Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van der Wall E, Slaper-Cortenbach IC, Schornagel JH. Rodenhuis S, et al. J Clin Oncol. 1996 May;14(5):1473-83. doi: 10.1200/JCO.1996.14.5.1473. J Clin Oncol. 1996. PMID: 8622061 Clinical Trial.

3

Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.

Westermann AM, Dubbelman R, Baars JP, Moolenaar WH, Beijnen JH, Rodenhuis S. Westermann AM, et al. Cancer Chemother Pharmacol. 2000;46(1):57-62. doi: 10.1007/s002800000116. Cancer Chemother Pharmacol. 2000. PMID: 10912579 Clinical Trial.

4

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.

Westermann AM, Holtkamp MM, Linthorst GA, van Leeuwen L, Willemse EJ, van Dijk WC, Nooijen WJ, Baars JW, Schornagel JH, Rodenhuis S. Westermann AM, et al. Ann Oncol. 1999 May;10(5):511-7. doi: 10.1023/a:1026427724108. Ann Oncol. 1999. PMID: 10415999 Free article.

5

Successful intraperitoneal suramin treatment of peritoneal mesothelioma.

Westermann AM, Dubbelman R, Moolenaar WH, Beijnen J, Rodenhuis S. Westermann AM, et al. Ann Oncol. 1997 Aug;8(8):801-2. doi: 10.1023/a:1008231901539. Ann Oncol. 1997. PMID: 9332690 Free article. No abstract available.

6

Growth factors in human ovarian cancer.

Westermann AM, Beijnen JH, Moolenaar WH, Rodenhuis S. Westermann AM, et al. Cancer Treat Rev. 1997 Mar;23(2):113-31. doi: 10.1016/s0305-7372(97)90024-4. Cancer Treat Rev. 1997. PMID: 9225962 Review. No abstract available.

7

[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].

Hooiveld EA, van Kuilenburg AB, Haanen JB, Westermann AM. Hooiveld EA, et al. Among authors: westermann am. Ned Tijdschr Geneeskd. 2004 Mar 27;148(13):626-8. Ned Tijdschr Geneeskd. 2004. PMID: 15083629 Dutch.

8

Malignant effusions contain lysophosphatidic acid (LPA)-like activity.

Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S. Westermann AM, et al. Ann Oncol. 1998 Apr;9(4):437-42. doi: 10.1023/a:1008217129273. Ann Oncol. 1998. PMID: 9636836 Free article.

9

Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.

Westermann AM, ten Bokkel Huinink WW, Rodenhuis S. Westermann AM, et al. Ann Oncol. 1996 Jan;7(1):104. doi: 10.1093/oxfordjournals.annonc.a010459. Ann Oncol. 1996. PMID: 9081381 Free article. No abstract available.

10

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C; Yondelis Ovarian Cancer Group. Del Campo JM, et al. Among authors: westermann am. Ann Oncol. 2009 Nov;20(11):1794-802. doi: 10.1093/annonc/mdp198. Epub 2009 Jun 25. Ann Oncol. 2009. PMID: 19556318 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page